Signios Bio and Illumina Announce Grant to Maximize Discovery Power with Industry's Largest NGS-Based Proteomics Panel
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Signios Biosciences ('Signios Bio'), a science-first biotechnology company leading in multiomics and AI-powered bioinformatics, in collaboration with Illumina, announced today an Illumina-sponsored grant for Early Access to Illumina Protein Prep 9.5K™. Powered by SOMAmer® technology, this next-generation sequencing (NGS)-based platform enables comprehensive proteomic profiling of plasma and serum.
Illumina Protein Prep 9.5K™ utilizes slow off-rate modified aptamers to selectively bind approximately 9,500 unique human protein targets, with quantification performed on the NovaSeq™ sequencing system.
A panel of experts from Signios Bio and Illumina will select a grant winner. The grant will cover the cost of proteomic profiling for up to 170 samples (plasma or serum) using the Early Access Illumina Protein Prep 9.5K™, managed by Signios Bio.
The specifics of the grant program and the application process can be found at www.signiosbio.com/illumina-grant.
Signios Bio and Illumina will work closely with the awardee to support data analysis and publication efforts using the Illumina Connected Multiomics platform, a powerful tertiary analysis solution for integrating multiomics datasets, conducting pathway and differential expression analyses, and generating interactive visualizations. The awardee, following completion of the study, will have an opportunity to present their findings at upcoming Signios Bio and/or Illumina events.
Deadline for application submission is June 27 th, 2025, 11:59 PM PT using the link - www.signiosbio.com/illumina-grant.
About Signios Biosciences
Signios Biosciences, (formerly named MedGenome US Research) is a multiomics and bioinformatics company dedicated to revealing the intricate signals within biological data. By combining cutting-edge AI, multiomic technologies, and scientific partnership, Signios Bio enables the discovery and development of next-generation therapies and diagnostics that are more inclusive, effective, and transformative.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
Aravax Appoints Louise Peacock as Chief Regulatory and Quality Officer as it Prepares for Phase 3 Development
MELBOURNE, Australia and OXFORD, United Kingdom, June 02, 2025 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifying immunotherapies for food allergy, today announces the appointment of Louise Peacock as Chief Regulatory and Quality Officer, based at the Company's Oxford, UK site. With more than 35 years in the pharmaceutical industry, Louise brings extensive and highly relevant experience to Aravax having previously made key contributions to the approval of Palforzia® - the first and only FDA approved oral immunotherapy (OIT) to treat peanut allergy. Louise has held prior roles as Chief Regulatory Affairs and Quality Officer at Vaderis Therapeutics AG and Alladapt Immunotherapeutics and was Head of Pharma R&D at Nestle Health Science/Aimmune Therapeutics (acquired by Nestle Health Science in 2020) where she had broad responsibilities for global regulatory affairs across pharma products in food allergy, gastrointestinal and metabolic disorders. Whilst at Aimmune, Louise was responsible for activities supporting the development and marketing approvals for Palforzia® in the US, EU, UK and Switzerland. Louise's early career included senior positions at Abbott Laboratories, Auxilium Pharmaceuticals, Intermune and Circassia. Louise received her BSc (Hons) Pharmacology from Kings College, London and her LLB (Hons) from the University of West London. Louise Peacock, Chief Regulatory and Quality Officer of Aravax, said, 'Despite recent advances, food allergy remains an ever-growing and life-threatening problem around the world and there is a critical need for better therapies. Having followed Aravax's developments, I am convinced that PVX108 has the potential to be a life-changing alternative for patients with peanut allergy. I look forward to joining what is a world-class team and to bringing my experience to bear on the rapid further development of PVX108 and other products.' Dr Pascal Hickey, CEO of Aravax, said, 'Louise's experience in regulatory affairs in the field of food allergy is unique. It spans all the major regulatory bodies and multiple programs including the successful approval of Palforzia®. We are enormously excited that she is joining the Aravax team.' About Aravax Aravax is a clinical stage biotechnology company focused on revolutionising the treatment of food allergies with next-generation, disease-modifying immunotherapies which are safer and more convenient than existing approaches. Aravax's proprietary platform generates engineered peptides that precisely retrain the immune system and restore the body's ability to safely tolerate food allergens, without putting patients at risk of treatment-induced acute allergic reactions, including anaphylaxis. The lead product, PVX108, is currently being studied in an international Phase 2 trial for the treatment of peanut allergy. Aravax is also developing a pipeline of products tackling additional significant food allergy indications. Aravax is an international company headquartered in Melbourne, Australia with a subsidiary in Oxford, UK and operations in USA and Europe. Aravax's investors include leading international and Australian investors including Novartis Venture Fund, Brandon Capital, Tenmile, Breakthrough Victoria, Uniseed and UniSuper. For more information visit: For further information please contact Media – AustraliaKirrily Davis, E: kdavis@ M: +61 (0)401 220228 Media - InternationalSue Charles, Charles Consultants E: M: +44 (0)7968 726585Chris Gardner, E: Chris@ M: +44 (0)7956 031077Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
34 minutes ago
- Business Upturn
CEOs of The LYCRA Company and Qore® Join Global Fashion Summit Lineup
Wilmington, Del., United States: The LYCRA Company, a global leader in developing sustainable fibers and solutions for the apparel industry, announced today that its CEO, Gary Smith, is a speaker at the Global Fashion Summit: Copenhagen Edition 2025. He will be joined on stage by Jon Veldhouse, CEO of Qore®, the maker of QIRA®, a next-generation BDO and a key ingredient in bio-derived LYCRA® fiber, which is launching later this year. This press release features multimedia. View the full release here: LYCRA® brand and QIRA® are principal sponsors of the Global Fashion Summit: Copenhagen Edition 2025. The brands are exhibiting at the event, where they will promote bio-derived LYCRA® fiber made with QIRA®, derived from field corn, to help make fashion more sustainable. Smith and Veldhouse will discuss the development of this sustainable fiber made from annually renewable field corn during their Fireside Chat: From Farm to Fashion. Their session takes place on Wednesday, June 4, at 3:35 CEST in the DR Concert Hall. The discussion will be moderated by Amy Nguyen, a researcher, writer, and founder of Sustainable & Social. This is the first time both companies are participating in the Global Fashion Summit, a premier platform focused on sustainability in the fashion industry. The companies have a prominent exhibit space for attendees to learn more about bio-derived LYCRA® fiber made with QIRA®. Here, visitors can be transported to the Qore® site and cornfields in Iowa through a virtual reality experience. Bio-derived LYCRA® EcoMade fiber will be the world's first large-scale, commercially available renewable elastane. It delivers equivalent performance to the original LYCRA® fiber and serves as a one-to-one replacement with no re-engineering of fabrics, processes, or garment patterns required. The product contains 70 percent renewable content and can potentially reduce the carbon footprint of LYCRA® fiber by up to 44 percent*. The LYCRA Company holds patents related to this renewable fiber in several regions including Europe. 'We're proud to join the Global Fashion Summit for the first time and showcase how collaboration can accelerate a more sustainable future for fashion,' said Gary Smith, CEO of The LYCRA Company. 'Partnering with Qore® has enabled us to scale innovation that is renewable and ready to meet the demands of global fashion brands striving to meet their sustainability goals.' The newly constructed Qore® site in Eddyville, Iowa, began operating last month and has started producing QIRA®. The company will host a grand opening celebration in July. 'Starting production at our new state-of-the-art facility marks a major step forward—not just for Qore®, but for the entire industry,' said Jon Veldhouse, CEO of Qore®. 'With QIRA® now being made in Iowa from annually renewable field corn, we're turning sustainable innovation into reality and helping our partners bring next-generation materials to market.' Learn more about this renewable offering by visiting *Estimate from Cradle-to-Gate Screening LCA for a representative LYCRA® fiber manufacturing facility, June 2022, prepared by Ramboll Americas Engineering Solutions, Inc. About The LYCRA Company The LYCRA Company is a leading global fiber and technology solutions provider to the apparel and personal care industries committed to offering sustainable products using renewable, pre-, and post-consumer recycled ingredients that reduce waste and help set the stage for circularity. Headquartered in Wilmington, Delaware, United States, it owns the LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX® and TACTEL® brands. The LYCRA Company adds value to its customers' products by offering unique innovations that meet the consumer's need for comfort and lasting performance. Learn more at About Qore® LLC Formed through a joint venture by Cargill and HELM AG, Qore® helps leading brands replace fossil-based chemistries with bio-derived intermediates. At the heart of the joint venture is the production of QIRA®, the next-generation bio-derived 1,4-butanediol (BDO). Made biologically through the fermentation of plant-based sugars, QIRA® can save up to 86% of greenhouse gas emissions when replacing today's widely used chemical intermediates made from traditional fossil sources. Bio-derived QIRA® can be used the same way as its fossil counterpart but with significantly better environmental performance. For more information and inquiries, visit About The Global Fashion Summit Global Fashion Summit is a leading international forum for sustainability in fashion, presented by Global Fashion Agenda (GFA). Convening major decision makers from across the world, the forum was first launched in 2009 and has become a nexus for agenda-setting discussions and presentations on the most critical environmental, social and ethical issues facing our industry and planet, all intended to spark urgent action and accelerate impact in the industry. Learn more at LYCRA® is a trademark of The LYCRA Company. QIRA® is a trademark of Qore®. View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Yahoo
37 minutes ago
- Yahoo
UAE Prenatal Testing Market to Triple by 2033: Driven by Tech Advancements and Maternal Health Awareness
Key drivers include increasing maternal age, healthcare advancements, and government support for early fetal screening. The market benefits from the rise in medical tourism and global diagnostic partnerships, despite challenges like cultural sensitivities and a lack of genetic counseling. Major players such as Eurofins, Roche, and Illumina enhance the UAE's prenatal care through innovative technologies and strategic partnerships. UAE Non-Invasive Prenatal Testing Market Dublin, June 02, 2025 (GLOBE NEWSWIRE) -- The "UAE Non-Invasive Prenatal Testing Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to UAE Non-Invasive Prenatal Testing Market is expected to reach US$ 64.46 million by 2033 from US$ 21.04 million in 2024, with a CAGR of 13.25% from 2025 to 2033. The UAE's non-invasive prenatal testing market is growing due to a number of factors, including growing maternal age, better access to healthcare, increasing awareness, government assistance, the need for early fetal screening, and a rise in incidences of genetic disorders. UAE Non-Invasive Prenatal Testing Industry OverviewDue to improvements in genetic screening technology and growing awareness among pregnant parents, the non-invasive prenatal testing (NIPT) market in the United Arab Emirates (UAE) is expanding steadily. NIPT uses a straightforward blood test from the mother to safely and effectively identify chromosomal abnormalities in the fetus. Because of its accuracy, early detection potential, and low danger in comparison to more conventional invasive techniques like amniocentesis, it has becoming more and more popular in the United Arab Emirates. Both public and commercial healthcare organizations are implementing NIPT as a common prenatal screening procedure as healthcare standards rise and prenatal care becomes more maternal age is a major risk factor for chromosomal abnormalities like Down syndrome, which raises the need for accurate prenatal screening and is one of the main causes driving this industry's rise. Furthermore, expanding insurance coverage, the presence of foreign healthcare practitioners, and the UAE government's initiatives to improve genetic health services all help to increase NIPT's accessibility and acceptability. The market is also supported by the nation's growing medical tourism industry, which draws patients from nearby areas looking for cutting-edge prenatal diagnostics, especially in locations like Dubai and Abu its promise, the UAE NIPT industry is beset by issues including low awareness among specific demographic groups and the exorbitant expense of testing for those without insurance. These obstacles are being addressed, meanwhile, by continued public education campaigns, the incorporation of genetics into national healthcare plans, and partnerships with international diagnostics firms. With advancements in bioinformatics and non-invasive technologies anticipated to further improve the precision and reach of prenatal screening services, the NIPT sector in the United Arab Emirates is well-positioned for sustained development as precision medicine continues to Drivers for the UAE Non-Invasive Prenatal Testing Market Supportive Government PoliciesThe UAE's non-invasive prenatal testing (NIPT) sector is expanding thanks in large part to supportive government legislation. As part of its larger national healthcare policy, the government has made maternal and fetal health a top priority, investing heavily in early diagnostic technologies and updating hospital infrastructure. The National Genome Strategy and the UAE's Vision 2031 initiatives center on incorporating cutting-edge genetic technology into standard medical treatment. While regulatory agencies make ensuring that these technologies are used in a safe and moral manner, public health campaigns also seek to increase awareness about prenatal screening. These initiatives, together with advantageous laws and alliances with international biotech companies, are creating a healthcare climate that encourages innovation and the broad use of NIPT throughout the Tourism GrowthThe non-invasive prenatal testing (NIPT) industry in the United Arab Emirates is growing due in large part to the rise of medical tourism, particularly in locations like Dubai and Abu Dhabi. The nation has established itself as a regional center for top-notch, specialized medical treatment, drawing clients from Asia, Africa, and the Middle East. The UAE's highly developed healthcare system, internationally recognized facilities, and access to state-of-the-art diagnostic tools like NIPT attract patients from outside. For pregnant moms looking for early and precise fetal screening, prenatal care facilities that offer individualized attention and minimal wait periods are particularly alluring. The UAE's standing as a destination for cutting-edge prenatal diagnostics is further reinforced by government funding for healthcare tourism and continuous initiatives to enhance service of Global Diagnostic CompaniesOne of the main factors propelling the non-invasive prenatal testing (NIPT) industry's expansion in the United Arab Emirates is the arrival of international diagnostic and genomics firms. To increase access to cutting-edge prenatal screening technology, foreign companies are establishing strategic alliances with regional healthcare providers, labs, and governmental organizations. The accuracy, speed, and scope of NIPT services are improved by these partnerships' introduction of cutting-edge technologies including high-throughput sequencing and AI-powered data processing. Furthermore, foreign actors raise the general level of prenatal care in the United Arab Emirates by assisting with knowledge transfer, workforce training, and adherence to international quality standards. The country's larger objectives of becoming a regional leader in precision healthcare and genomic medicine are supported by this infusion of knowledge and in the UAE Non-Invasive Prenatal Testing Market Cultural and Religious SensitivitiesThe UAE's adoption of non-invasive prenatal testing (NIPT) is significantly hampered by cultural and religious sensitivities. The ethical ramifications of prenatal testing, especially with regard to possible judgments about pregnancy termination, might restrict acceptability in an area where traditional values and religious views are crucial in family and healthcare decisions. Because of religious beliefs about the sanctity of life, worries about disrupting natural processes, or fears of social disapproval, some families might be reluctant to undergo genetic testing. Even when NIPT is advised by a doctor, these issues may cause reluctance to choose it. Building understanding and confidence in prenatal screening necessitates ethical counseling, culturally relevant public education, and collaboration with community and religious of Genetic Counseling ServicesOne major obstacle to the efficient use of non-invasive prenatal testing (NIPT) in the United Arab Emirates is the lack of qualified genetic counselors. Even though NIPT's technology is sophisticated and becoming more widely available, many patients may not have the assistance they need to understand complicated genetic data. Expectant parents may misinterpret test findings without the right counseling, which might cause needless worry or poor choices. In a culturally diverse nation like the United Arab Emirates, where language proficiency and cultural awareness are crucial for successful communication, this disparity is especially significant. Existing healthcare providers are likewise strained by the shortage of skilled workers. To remedy this deficiency, it is imperative to integrate remote or tele-counseling services, expand training programs, and provide incentives for genetic counseling expertise. Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $21 Million Forecasted Market Value (USD) by 2033 $64.5 Million Compound Annual Growth Rate 13.2% Regions Covered United Arab Emirates Report Scope: UAE Non-Invasive Prenatal Testing Market Segment Component Instruments Kits and Reagents Services Application Down Syndrome (Trisomy 21) Edwards Syndrome (Trisomy 18) Patau Syndrome (Trisomy 13) Turner Syndrome Other Applications End User Hospitals Diagnostic Labs The key players have been analyzed by: Overview Key Persons Recent Development & Strategies Financial Insights Key Players Analyzed: Eurofins Scientific F. Hoffmann-La Roche Ltd Invitae Corporation Illumina Inc. Natera Inc. Centogene NV Qiagen For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment UAE Non-Invasive Prenatal Testing Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
